Prevention & lipidsSecondary analysis
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
- Post hoc analysis of the REDUCE-IT randomised trial
Authors' conclusion
Baseline Lp(a) concentration was prognostic for MACE among participants with elevated triglyceride levels receiving statin therapy. Importantly, IPE consistently reduced MACE across a range of Lp(a) levels, including among those with clinically relevant elevations.
Study context
- Population
- Statin-treated patients with established CVD or age ≥50 years with DM and ≥1 additional risk factor, fasting TG 1.69 to 5.63 mmol/L, LDL-C 1.06 to 2.59 mmol/L7,026 with baseline Lp(a)
- Participants
- 8,179 patients
- Comparison
- Icosapent ethyl (IPE) vs placebo across Lp levels
- Primary endpoint
- First MACE by baseline Lp(a) (≥50 or <50 mg/dL); relationship of continuous Lp(a) with first and total MACE
Primary result
As reported in the abstract
MACE by Lp(a) level
Event reductions with IPE did not vary across the range of Lp(a)
interaction P > 0.10
Lp(a) significantly related to first and total major adverse cardiovascular events (MACE)
P < 0.0001
Further findings
Baseline Lp(a) concentration
- Median Lp(a), mg/dL (Q1-Q3: 5.0-37.4)
- 11.6
- 7,026 participants with baseline Lp(a)
Original publication
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. Published 25 March 2024. doi:10.1016/j.jacc.2024.02.016
Summarised from the published abstract; every number is checked against it